Beta-blocker Rebound Phenomenon in an Adolescent with Graves’ Disease.
作者信息
Anık Ahmet
机构信息
Aydın Adnan Menderes University Faculty of Medicine, Department of Pediatrics, Clinic of Pediatric Endocrinology, Aydın, Turkey
出版信息
J Clin Res Pediatr Endocrinol. 2022 Dec 1;14(4):490-491. doi: 10.4274/jcrpe.galenos.2022.2022-6-2. Epub 2022 Jul 21.
Abstract
摘要
相似文献
1
Beta-blocker Rebound Phenomenon in an Adolescent with Graves’ Disease.一名患有格雷夫斯病的青少年的β受体阻滞剂反跳现象。
J Clin Res Pediatr Endocrinol. 2022 Dec 1;14(4):490-491. doi: 10.4274/jcrpe.galenos.2022.2022-6-2. Epub 2022 Jul 21.
2
Myasthenia gravis associated with Graves' disease in Japan.日本的重症肌无力与格雷夫斯病相关。
Jpn J Med. 1987 Feb;26(1):2-6. doi: 10.2169/internalmedicine1962.26.2.
3
The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.格雷夫斯病患者接受抗甲状腺药物治疗后短暂甲状腺毒症的患病率。
Thyroid. 2008 Jan;18(1):63-6. doi: 10.1089/thy.2007.0164.
4
Transient hyperthyroidism after withdrawal of antithyroid drugs in patients with Graves' disease.格雷夫斯病患者停用抗甲状腺药物后出现的短暂性甲状腺功能亢进。
Endocr J. 2004 Apr;51(2):213-7. doi: 10.1507/endocrj.51.213.
5
Outcomes of Early-Pregnancy Antithyroid Drug Withdrawal in Graves' Disease: A Preliminary Prospective Follow-Up Study.格雷夫斯病早期妊娠抗甲状腺药物停药的结局：一项初步前瞻性随访研究。
Thyroid. 2022 Aug;32(8):983-989. doi: 10.1089/thy.2022.0088. Epub 2022 Jul 18.
6
Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.Graves 甲亢患者停用抗甲状腺药物后的长期缓解：具有预后价值的参数。
Endocrine. 2019 Feb;63(2):316-322. doi: 10.1007/s12020-018-1785-z. Epub 2018 Oct 17.
7
A 27-year-old woman diagnosed as polycystic ovary syndrome associated with Graves' disease.一名27岁女性被诊断为多囊卵巢综合征合并格雷夫斯病。
Intern Med. 2011;50(19):2185-9. doi: 10.2169/internalmedicine.50.5475. Epub 2011 Oct 1.
8
Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentrations and porcine thyroid cells.使用高浓度聚乙二醇和猪甲状腺细胞检测格雷夫斯病中促甲状腺素抗体的灵敏检测方法的临床意义
Endocr J. 1999 Jun;46(3):397-403. doi: 10.1507/endocrj.46.397.
9
A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves' disease.一项在中国Graves病患者中比较甲巯咪唑治疗联合或不联合外源性L-甲状腺素的随机前瞻性试验的6年随访。
Exp Clin Endocrinol Diabetes. 2014 Nov;122(10):564-7. doi: 10.1055/s-0034-1377045. Epub 2014 Aug 20.
10
Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.甲巯咪唑治疗2年对甲状腺功能亢进型格雷夫斯病患者循环中白细胞介素-4、免疫球蛋白E、促甲状腺素受体抗体及甲状腺刺激抗体的影响。
Endocr J. 2006 Dec;53(6):783-8. doi: 10.1507/endocrj.k06-054. Epub 2006 Sep 19.
引用本文的文献
1
Pediatric Graves' Disease: Surgical Interventions in a Single Institution - A Comprehensive Case Series.儿童格雷夫斯病：单机构的手术干预——综合病例系列
Indian J Otolaryngol Head Neck Surg. 2024 Oct;76(5):4846-4850. doi: 10.1007/s12070-024-04902-6. Epub 2024 Jul 18.
本文引用的文献
1
2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.2022年欧洲甲状腺协会儿童格雷夫斯病管理指南
Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073.
2
Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies.β受体阻滞剂反跳现象很重要，但我们尚不清楚其定义、发生率或最佳预防策略。
Hypertens Res. 2020 Jul;43(7):591-596. doi: 10.1038/s41440-020-0449-6. Epub 2020 May 7.
3
Hyperthyroidism in childhood: causes, when and how to treat.儿童甲状腺功能亢进症：病因、治疗时机及治疗方法
J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1(Suppl 1):50-6. doi: 10.4274/jcrpe.854.
4
Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule.通过延长小剂量普萘洛尔给药方案预防普萘洛尔撤药机制。
Am J Cardiol. 1982 Mar;49(4):828-33. doi: 10.1016/0002-9149(82)91965-8.
5
Beta-adrenergic blocker withdrawal.β-肾上腺素能阻滞剂撤药反应
Am J Cardiol. 1987 May 15;59(13):26F-32F. doi: 10.1016/0002-9149(87)90038-5.
6
Mechanism of propranolol withdrawal phenomena.普萘洛尔撤药现象的机制。
Circulation. 1979 Jun;59(6):1158-64. doi: 10.1161/01.cir.59.6.1158.
Zotero 插件